Cooper Companies, Inc. COO
We take great care to ensure that the data presented and summarized in this overview for COOPER COMPANIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COO
View all-
Intermede Investment Partners LTD1.09MShares$109 Million2.52% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8143KShares$14.2 Million0.07% of portfolio
-
Brant Point Investment Management LLC New York, NY109KShares$10.9 Million2.96% of portfolio
-
Eaton Vance Management Boston, MA86.1KShares$8.58 Million0.03% of portfolio
-
Crystal Rock Capital Management54.2KShares$5.4 Million3.65% of portfolio
-
Wd Rutherford LLC39KShares$3.88 Million2.12% of portfolio
-
Cibc World Markets Corp New York, NY27KShares$2.69 Million0.02% of portfolio
-
Polaris Wealth Advisory Group, LLC5.83KShares$581,0420.14% of portfolio
-
Ferguson Wellman Capital Management, Inc3.34KShares$332,7640.01% of portfolio
-
Allstate Investment Management CO Northbrook, IL3.03KShares$301,8780.03% of portfolio
Latest Institutional Activity in COO
Top Purchases
Top Sells
About COO
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Insider Transactions at COO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 19
2024
|
Albert G White Iii President & CEO |
SELL
Open market or private sale
|
Direct |
114,992
-21.2%
|
$12,649,120
$110.92 P/Share
|
Sep 19
2024
|
Albert G White Iii President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
114,992
+29.09%
|
$4,944,656
$43.83 P/Share
|
Sep 10
2024
|
Agostino Ricupati SVP & CAO |
SELL
Open market or private sale
|
Direct |
1,601
-24.94%
|
$172,908
$108.03 P/Share
|
Sep 05
2024
|
Brian G Andrews EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
24,788
-78.94%
|
$2,602,740
$105.9 P/Share
|
Sep 05
2024
|
Brian G Andrews EVP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,788
+33.34%
|
$941,944
$38.37 P/Share
|
Sep 04
2024
|
Daniel G Mc Bride EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
114,992
-31.2%
|
$12,189,152
$106.18 P/Share
|
Sep 04
2024
|
Daniel G Mc Bride EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
114,992
+41.86%
|
$4,944,656
$43.83 P/Share
|
Apr 01
2024
|
Agostino Ricupati SVP & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,053
-14.09%
|
$104,247
$99.24 P/Share
|
Apr 01
2024
|
Agostino Ricupati SVP & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,076
+21.74%
|
-
|
Apr 01
2024
|
Maria Rivas |
BUY
Exercise of conversion of derivative security
|
Direct |
2,892
+50.0%
|
-
|
Apr 01
2024
|
Robert S Weiss |
BUY
Exercise of conversion of derivative security
|
Direct |
3,180
+1.1%
|
-
|
Apr 01
2024
|
William A Kozy |
BUY
Exercise of conversion of derivative security
|
Direct |
3,036
+9.69%
|
-
|
Apr 01
2024
|
Lawrence Erik Kurzius |
BUY
Exercise of conversion of derivative security
|
Direct |
1,056
+50.0%
|
-
|
Apr 01
2024
|
Colleen Jay |
BUY
Exercise of conversion of derivative security
|
Direct |
2,892
+9.74%
|
-
|
Apr 01
2024
|
Cynthia L Lucchese |
BUY
Exercise of conversion of derivative security
|
Direct |
2,892
+36.93%
|
-
|
Apr 01
2024
|
Teresa S Madden |
BUY
Exercise of conversion of derivative security
|
Direct |
2,892
+23.08%
|
-
|
Mar 22
2024
|
Gary S Petersmeyer |
BUY
Bona fide gift
|
Indirect |
655
+30.07%
|
-
|
Mar 22
2024
|
Gary S Petersmeyer |
SELL
Bona fide gift
|
Indirect |
655
-11.56%
|
-
|
Mar 18
2024
|
Agostino Ricupati SVP & CAO |
SELL
Open market or private sale
|
Direct |
54,724
-42.98%
|
$5,472,400
$100.89 P/Share
|
Mar 18
2024
|
Agostino Ricupati SVP & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
54,724
+25.57%
|
$2,955,096
$54.14 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 658K shares |
---|---|
Bona fide gift | 5.2K shares |
Payment of exercise price or tax liability | 3.47K shares |
---|---|
Open market or private sale | 633K shares |
Bona fide gift | 35.5K shares |